What we're doing with the Prescribed List

Reforms

Recent reforms to improve the Prescribed List have been completed.

See a full list of reform measures.

Read our summary of the reform objectives and achievements.

Evaluation

An independent evaluation of the reforms is under way to evaluate the outcomes of the reforms.

About the evaluation

Nous Group is evaluating the reforms, with the support of an external advisory group and an internal evaluation team.

The evaluation is looking at:

• whether the reforms are being implemented as intended
• whether the reforms are achieving the expected outcomes
• the ongoing and future directions, opportunities and priorities for the reforms.

Status

The interim evaluation report 2 of the Prescribed List reforms is now available. The interim evaluation report 2 covers the period from July 2024 to June 2025. It builds on the interim evaluation report 1.

Findings from interim evaluation report 2 reinforce and provide further commentary on many of the findings from interim evaluation report 1.

The interim evaluation report 1 covers the period from May 2021 to June 2024 and reports on whether the reforms are:

• being implemented as intended
• achieving the expected outcomes.

The baseline evaluation report was published on 18 October 2024 and:

• provides the status of the key projects at the start of the reforms
• outlines how each project will contribute to achieving the reform objectives.

Future reports

Nous Group will provide us with the final evaluation report in 2026.

Consultation

We worked with stakeholders to create a strong and fit-for-purpose Prescribed List.

Learn about our reform consultations.

We will advise stakeholders of any future consultations.